Unknown

Dataset Information

0

Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice.


ABSTRACT: Therapeutic strategies are needed for the treatment of amyotrophic lateral sclerosis (ALS). One potential target is matrix metalloproteinase-9 (MMP-9), which is expressed only by fast motor neurons (MNs) that are selectively vulnerable to various ALS-relevant triggers. Previous studies have shown that reduction of MMP-9 function delayed motor dysfunction in a mouse model of familial ALS. However, given that the majority of ALS cases are sporadic, we propose preclinical testing in a mouse model which may be more clinically translatable: rNLS8 mice. In rNLS8 mice, neurodegeneration is triggered by the major pathological hallmark of ALS, TDP-43 mislocalization and aggregation. MMP-9 was targeted in 3 different ways in rNLS8 mice: by AAV9-mediated knockdown, using antisense oligonucleotide (ASO) technology, and by genetic modification. All 3 strategies preserved the motor unit during disease, as measured by MN counts, tibialis anterior (TA) muscle innervation, and physiological recordings from muscle. However, the strategies that reduced MMP-9 beyond the motor unit lead to premature deaths in a subset of rNLS8 mice. Therefore, selective targeting of MMP-9 in MNs could be beneficial in ALS, but side effects outside of the motor circuit may limit the most commonly used clinical targeting strategies.

SUBMITTER: Spiller KJ 

PROVIDER: S-EPMC7053168 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice.

Spiller Krista J KJ   Khan Tahiyana T   Dominique Myrna A MA   Restrepo Clark R CR   Cotton-Samuel Dejania D   Levitan Maya M   Jafar-Nejad Paymaan P   Zhang Bin B   Soriano Armand A   Rigo Frank F   Trojanowski John Q JQ   Lee Virginia M-Y VM  

Neurobiology of disease 20181117


Therapeutic strategies are needed for the treatment of amyotrophic lateral sclerosis (ALS). One potential target is matrix metalloproteinase-9 (MMP-9), which is expressed only by fast motor neurons (MNs) that are selectively vulnerable to various ALS-relevant triggers. Previous studies have shown that reduction of MMP-9 function delayed motor dysfunction in a mouse model of familial ALS. However, given that the majority of ALS cases are sporadic, we propose preclinical testing in a mouse model w  ...[more]

Similar Datasets

| S-EPMC6802294 | biostudies-literature
| S-EPMC7885352 | biostudies-literature
| S-EPMC6096729 | biostudies-literature
| S-EPMC5847883 | biostudies-literature
| S-EPMC3820133 | biostudies-literature
| S-EPMC7035286 | biostudies-literature
| S-EPMC10369818 | biostudies-literature
| S-EPMC3248298 | biostudies-literature
| S-EPMC9107273 | biostudies-literature
| S-EPMC5427168 | biostudies-literature